On April 9, 2024, the Nuvation Bio Inc. completed its previously announced acquisition (the ?Acquisition?) of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (?AnHeart?), pursuant to that certain Agreement and Plan of Merger (the ?Merger Agreement?), by and among the Company, AnHeart, Artemis Merger Sub I Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company. In accordance with the Merger Agreement, on April 9, 2024, effective upon the closing of the Acquisition, Dr. Junyuan (Jerry) Wang and Dr. Xiangmin (Min) Cui, Ph.D. were appointed as Class I and Class III directors, respectively, to the Company?s board of the directors (the ?Board?). The term for Class III directors expires at this year?s annual meeting of the Company?s stockholders; the term for Class I directors expires at next year?s annual meeting of the Company?s stockholders.

Dr. Wang, age 51, co-founded AnHeart in 2018, where he has served as Chief Executive Officer since AnHeart?s formation and leads the in-license and development of taletrectinib and safusidenib. From June 2014 to September 2018, Dr. Wang was the Head of Global Biostatistics, EPI, and Medical Writing (GBEM) China at Merck Serono. Prior to that, from September 2011 to June 2014, he served as Director of Biostatistics at Bristol Myers Squibb.

Prior to that, Dr. Wang served as Director of Biostatistics at Pfizer from October 2007 to September 2011. Prior to that, from January 2006 to October 2007, Dr. Wang served as Director of Biostatistics for The Medicines Company. Prior to that, he served as a senior biometrician at Merck and Co.

Dr. Wang made key contributions to the successful NDAs of Bosulif and Eliquis, and the latter became a multi-billion blockbuster drug. He has extensive experience with global health authorities including FDA, EMA, PMDA, and NMPA. He also previously served in leadership roles for professional societies and on the programming committee of leading scientific conferences.

Dr. Wang earned his B.S. in Mathematics from the University of Science and Technology of China and his Ph.D. in Statistics from Iowa State University. Dr. Cui, age 55, founded Decheng Capital LLC in 2011, where he has served as Managing Director since the firm?s formation. Currently, Dr. Cui serves on the board of directors of Alpine Immune Sciences Inc., a publicly traded clinical stage biopharmaceutical company.

Dr. Cui also currently serves on the board of directors of several privately held biotechnology and medical technology companies, including Accuragen Inc., Nanjing Bioheng Biotech Co. Ltd., EpimAb Biotherapeutics Inc., Harton Inc., ImmPACT Bio USA Inc., Mammoth Biosciences Inc., Mirvie Inc., Shape Therapeutics Inc. and VintaBio Inc. Dr. Cui is also a member of the board of trustees at Western University of Health Sciences. Dr. Cui previously served on the board of directors of other biotechnology and medical technology companies, including ARMO BioSciences (acquired by Eli Lilly & Co), Cirina Ltd. (acquired by GRAIL Inc.), Cue Health Inc., GeneWEAVE Biosciences Inc. (acquired by Roche Molecular Systems Inc.), GenturaDx Inc. (acquired by Luminex Corporation), GRAIL (acquired by Illumina Inc.), Ion Torrent Systems Inc. (acquired by Life Technologies Corporation), Sino Medical-Device Technology Co.

Ltd. and Velos Biopharma (acquired by Merck & Co.). From 2006 to 2011, Dr. Cui served as a principal at Bay City Capital, a venture capital firm. Prior to that, Dr. Cui served as Director of Strategic Investment for the Southern Research Institute, a not-for-profit organization concentrating on drug research and development.

Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals, a U.S. biotech company, and Hucon Biopharmaceuticals, a PRC pharmaceutical company. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. Dr. Cui received his B.S. and M.S. in Molecular Biology from Peking University and his Ph.D. in Cancer Biology from Stanford University.